PDF herunterladen
Homœopathic Links 2020; 33(02): 099-103
DOI: 10.1055/s-0040-1712525
Original Article
Thieme Medical and Scientific Publishers Private Ltd.

Prevention of Panton-Valentine Toxin-Mediated Leucocyte Destruction Depending on the Ultra-Diluted Staphylococcinum Potency Gradient

Pritam Goswami
1   Department of Medicine, Mahesh Bhattacharyya Homoeopathic Medical College and Hospital, Howrah, West Bengal, India
,
Sayak Ghosh
2   Department of Practice of Medicine, Calcutta Homoeopathic Medical College and Hospital, Kolkata, West Bengal, India
,
Sk Swaif Ali
3   Mahesh Bhattacharyya Homoeopathic Medical College and Hospital, Howrah, West Bengal, India
,
Anamika Basu
3   Mahesh Bhattacharyya Homoeopathic Medical College and Hospital, Howrah, West Bengal, India
,
Joydeep Khanra
4   Clinical Research Unit, Central Council for Research in Homoeopathy, Siliguri, West Bengal, India
,
Shubhamoy Ghosh
5   Department of Pathology and Microbiology, Mahesh Bhattacharyya Homoeopathic Medical College and Hospital, Howrah, West Bengal, India
,
Satadal Das
6   Department of Microbiology, Peerless Hospital and B. K. Roy Research Centre, Kolkata, West Bengal, India
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
02. Juni 2020 (online)

    Lizenzen und Reprints

Abstract

Background Panton-Valentine toxin (PVT) is an important pathological marker of staphylococcal infection mediated by functional as well as morphological damage of the phagocytic cells. Human body being an ecological niche for the bacteria shows higher affinity toward staphylococcal infection. A steady escalation in mortality and morbidity associated with antibiotic resistance in gram-positive infections is an emerging threat all over the globe; thus, it is important to find out an alternative strategy that can diminish the virulence and pathogenicity of the bacteria. Staphylococcin is a colicin-type chemical secreted by Staphylococcus aureus helps to prevent growth of organisms other than its progenitor. In this study, we evaluated the efficacy of homoeopathic medicine Staphylococcinum against staphylococcal PVT at different potencies (6CH, 12CH, 30CH and 200CH).

Materials and Methods Different potencies of Staphylococcinum were administered in a leucocyte buffy coat preparation infected with staphylococcal suspension (0.5 McFarland's standard) along with control with alcohol. They were kept in incubator for 2 hours and then centrifuged at 1200 rpm for 5 minutes. Smears prepared on slides with centrifuged deposits stained by Preston and Morrell's modified Gram's method of staining and evaluated under the microscope.

Results It was observed that there was extensive destruction of leukocytes in control and 6CH potency, while the degree of destruction decreased markedly from 12CH to 200CH. At 200CH potency, leukocytes were almost normal, which clearly indicate the preventive action of Staphylococcinum against PVT. The mean percentages of intact leucocytes were 0.73, 0.93, 10.00, 27.67 and 65.00 in control, 6CH, 12CH, 30CH and 200CH potencies, respectively.

Conclusion The finding may help in the use of this medicine in moribund patients in cases of disseminated S. aureus infection as there is no known side effect of the medicine. However, in vivo study is necessary before such use in those cases.

Keywords

Staphylococcus aureus - Panton-Valentine leucocidins - Staphylococcinum - antibiotic resistance - homeopathy

Supplementary Material

 

  • References

  • 1 Sangvik M. Staphylococcus aureus Colonisation and Host-Microbe Interactions [PhD thesis]. Tromsø, Norway: University of Tromsø UIT; 2013
    Google Scholar
  • 2 Muenks CE, Hogan PG, Wang JW, Eisenstein KA, Burnham CD, Fritz SA. Diversity of Staphylococcus aureus strains colonizing various niches of the human body. J Infect 2016; 72 (06) 698-705
    CrossrefPubMedGoogle Scholar
  • 3 Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 2003; 48 (06) 1429-1449
    CrossrefPubMedGoogle Scholar
  • 4 Götz F, Bannerman T, Schleifer KH. The Genera Staphylococcus and Macrococcus. In: Dworkin M, Falkow S, Rosenberg E, Schleifer KH, Stackebrandt E. , eds. The Prokaryotes. New York, NY: Springer; 2006
  • 5 McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006; 12 (11) 1715-1723
    CrossrefPubMedGoogle Scholar
  • 6 Center for Disease Control and Prevention, USA, Bulletin CDC 24/7: Saving Lives, Protecting People, Antibiotic/Antimicrobial Resistance; 2019
    PubMed
  • 7 Cornaglia G. Fighting infections due to multidrug-resistant Gram-positive pathogens. Clin Microbiol Infect 2009; 15 (03) 209-211
    PubMedGoogle Scholar
  • 8 Laxminarayan R, Chaudhury RR. Antibiotic resistance in India: drivers and opportunities for action. PLoS Med 2016; 13 (03) e1001974
    CrossrefPubMedGoogle Scholar
  • 9 Walia K, Madhumathi J, Veeraraghavan B. , et al. Establishing antimicrobial resistance surveillance & research network in India; journey so far. Indian J Med Res 2019; 149 (02) 164-179
    CrossrefPubMedGoogle Scholar
  • 10 National Treatment Guidelines for Antimicrobial Use in Infectious Disease. National Centre for Disease Control, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, (Version 1.0, 2016 http://pbhealth.gov.in/AMRguideline7001495889.pdf
    PubMed
  • 11 Indian Network for Surveillance of Antimicrobial Resistance (INSAR) group, India. Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence & susceptibility pattern. Indian J Med Res 2013; 137 (02) 363-369
    PubMedGoogle Scholar
  • 12 Patel AK, Patel KK, Patel KR, Shah S, Dileep P. Time trends in the epidemiology of microbial infections at a tertiary care center in west India over last 5 years. J Assoc Physicians India 2010; 58 (58) 37-40
    PubMedGoogle Scholar
  • 13 Chandy SJ, Naik GS, Balaji V, Jeyaseelan V, Thomas K, Lundborg CS. High cost burden and health consequences of antibiotic resistance: the price to pay. J Infect Dev Ctries 2014; 8 (09) 1096-1102
    CrossrefPubMedGoogle Scholar
  • 14 Dang A, Vallish BN. Can Health Technology Assessment (HTA) provide a solution to tackle the increasing health-care expenditure in India?. Indian J Public Health 2016; 60 (02) 138-141
    CrossrefPubMedGoogle Scholar
  • 15 Vesga O, Groeschel MC, Otten MF, Brar DW, Vann JM, Proctor RA. Staphylococcus aureus small colony variants are induced by the endothelial cell intracellular milieu. J Infect Dis 1996; 173 (03) 739-742
    CrossrefPubMedGoogle Scholar
  • 16 Kahl B, Herrmann M, Everding AS. , et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 1998; 177 (04) 1023-1029
    CrossrefPubMedGoogle Scholar
  • 17 Proctor RA, van Langevelde P, Kristjansson M, Maslow JN, Arbeit RD. Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin Infect Dis 1995; 20 (01) 95-102
    CrossrefPubMedGoogle Scholar
  • 18 Alonzo III F, Torres VJ. The bicomponent pore-forming leucocidins of Staphylococcus aureus. Microbiol Mol Biol Rev 2014; 78 (02) 199-230
    CrossrefPubMedGoogle Scholar
  • 19 Alonzo III F, Kozhaya L, Rawlings SA. , et al. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 2013; 493 (7430): 51-55
    PubMedGoogle Scholar
  • 20 Vandenesch F, Lina G, Henry T. Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: a redundant arsenal of membrane-damaging virulence factors?. Front Cell Infect Microbiol 2012; 2: 12
    PubMedGoogle Scholar
  • 21 Dal Peraro M, van der Goot FG. Pore-forming toxins: ancient, but never really out of fashion. Nat Rev Microbiol 2016; 14 (02) 77-92
    CrossrefPubMedGoogle Scholar
  • 22 Meyer F, Girardot R, Piémont Y, Prévost G, Colin DA. Analysis of the specificity of Panton-Valentine leucocidin and gamma-hemolysin F component binding. Infect Immun 2009; 77 (01) 266-273
    CrossrefPubMedGoogle Scholar
  • 23 Ozawa T, Kaneko J, Kamio Y. Essential binding of LukF of staphylococcal gamma-hemolysin followed by the binding of H gamma II for the hemolysis of human erythrocytes. Biosci Biotechnol Biochem 1995; 59 (06) 1181-1183
    CrossrefPubMedGoogle Scholar
  • 24 Kaneko J, Ozawa T, Tomita T, Kamio Y. Sequential binding of Staphylococcal gamma-hemolysin to human erythrocytes and complex formation of the hemolysin on the cell surface. Biosci Biotechnol Biochem 1997; 61 (05) 846-851
    CrossrefPubMedGoogle Scholar
  • 25 Koymans KJ, Vrieling M, Gorham Jr RD, van Strijp JA. Staphylococcal immune evasion proteins: structure, function, and host adaptation. Curr Top Microbiol Immunol 2017; 409: 441-489
    PubMedGoogle Scholar
  • 26 Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29: 707-735
    CrossrefPubMedGoogle Scholar
  • 27 Yoong P, Torres VJ. Counter inhibition between leukotoxins attenuates Staphylococcus aureus virulence. Nat Commun 2015; 6: 8125
    CrossrefPubMedGoogle Scholar
  • 28 Lee LY, Miyamoto YJ, McIntyre BW. , et al. The Staphylococcus aureus Map protein is an immunomodulator that interferes with T cell-mediated responses. J Clin Invest 2002; 110 (10) 1461-1471
    CrossrefPubMedGoogle Scholar
  • 29 Llewelyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002; 2 (03) 156-162
    CrossrefPubMedGoogle Scholar
  • 30 Ananthakrishnan N, Shanthi AK. ICMR's ethical guidelines for biomedical research on human participants: need for clarification. Indian J Med Ethics 2012; 9 (03) 207-209
    PubMedGoogle Scholar
  • 31 Pannuti CS, Grinbaum RS. An overview of nosocomial infection control in Brazil. Infect Control Hosp Epidemiol 1995; 16 (03) 170-174
    CrossrefPubMedGoogle Scholar
  • 32 Sahl H-G, Bierbaum G. Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria. Annu Rev Microbiol 1998; 52: 41-79
    CrossrefPubMedGoogle Scholar
  • 33 Gan XY, Yong L, Sun H. . The effect of HAS (highly agglutinative staphylococcin) on immune cells of cancer patients. Chinese Clinical Oncology Journal 2000; 27: 799-800
    PubMedGoogle Scholar
  • 34 Otto M. Staphylococcus aureus toxins. Curr Opin Microbiol 2014; 17: 32-37
    CrossrefPubMedGoogle Scholar
  • 35 Novick RP, Geisinger E. Quorum sensing in staphylococci. Annu Rev Genet 2008; 42: 541-564
    CrossrefPubMedGoogle Scholar
  • 36 Dunman PM, Murphy E, Haney S. , et al. Transcription profiling-based identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci. J Bacteriol 2001; 183 (24) 7341-7353
    CrossrefPubMedGoogle Scholar
  • 37 Benson MA, Ohneck EA, Ryan C. , et al. Evolution of hypervirulence by a MRSA clone through acquisition of a transposable element. Mol Microbiol 2014; 93 (04) 664-681
    CrossrefPubMedGoogle Scholar
  • 38 Heng NCK, Wescombe PA, Burton JP, Jack RW, Tagg JR. . The diversity of bacteriocins in Gram-positive bacteria. In: Riley MA, Chavan MA. , eds. Bacteriocins: Ecology and Evolution. New York, NY: Springer; 2007: 45-92
  • 39 Bierbaum G, Sahl H-G. Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol 2009; 10 (01) 2-18
    CrossrefPubMedGoogle Scholar
  • 40 Nissen-Meyer J, Rogne P, Oppegård C, Haugen HS, Kristiansen PE. Structure-function relationships of the non-lanthionine-containing peptide (class II) bacteriocins produced by gram-positive bacteria. Curr Pharm Biotechnol 2009; 10 (01) 19-37
    CrossrefPubMedGoogle Scholar
  • 41 Bastos MCF, Ceotto H, Coelho MLV, Nascimento JS. Staphylococcal antimicrobial peptides: relevant properties and potential biotechnological applications. Curr Pharm Biotechnol 2009; 10 (01) 38-61
    CrossrefPubMedGoogle Scholar
  • 42 Pag U, Sahl H-G. Multiple activities in lantibiotics--models for the design of novel antibiotics?. Curr Pharm Des 2002; 8 (09) 815-833
    CrossrefPubMedGoogle Scholar
  • 43 Kruszewska D, Sahl H-G, Bierbaum G, Pag U, Hynes SO, Ljungh A. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother 2004; 54 (03) 648-653
    CrossrefPubMedGoogle Scholar
  • 44 Eijsink VGH, Axelsson L, Diep DB, Håvarstein LS, Holo H, Nes IF. Production of class II bacteriocins by lactic acid bacteria; an example of biological warfare and communication. Antonie van Leeuwenhoek 2002; 81 (1-4): 639-654
    CrossrefPubMedGoogle Scholar
  • 45 Cotter PD, Hill C, Ross RP. Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Pept Sci 2005; 6 (01) 61-75
    CrossrefPubMedGoogle Scholar